Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
L287337-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $44.90 | |
L287337-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $157.90 | |
L287337-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $201.90 | |
L287337-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $588.90 | |
L287337-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $846.90 | |
L287337-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,485.90 |
Highly potent NMDA antagonist
Synonyms | AKOS030228809 | BRD-A28422058-001-01-0 | HMS3266P09 | SCHEMBL1993880 | L-689,560 | 4-[[anilino(oxo)methyl]amino]-5,7-dichloro-1,2,3,4-tetrahydroquinoline-2-carboxylic acid | 5,7-dichloro-4-(phenylcarbamoylamino)-1,2,3,4-tetrahydroquinoline-2-carboxylic ac |
---|---|
Specifications & Purity | Moligand™, ≥99%(HPLC) |
Biochemical and Physiological Mechanisms | Very potent antagonist at the glycine-NMDA site. |
Storage Temp | Room temperature |
Shipped In | Normal |
Grade | Moligand™ |
Action Type | ANTAGONIST |
Mechanism of action | Antagonist of GluN1;Antagonist of GluN2A;Antagonist of GluN2B;Antagonist of GluN2C;Antagonist of GluN2D |
Product Description |
L-689560 is a potent N-methyl-D-aspartate (NMDA) receptor antagonist that inhibits GluN1 glycine binding sites. L-689560 is widely used as a radiolabeling ligand in binding studies, as well as to study the role of NMDA receptors in normal nervous system processes and diseases
|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | 5,7-dichloro-4-(phenylcarbamoylamino)-1,2,3,4-tetrahydroquinoline-2-carboxylic acid |
---|---|
INCHI | InChI=1S/C17H15Cl2N3O3/c18-9-6-11(19)15-12(7-9)21-14(16(23)24)8-13(15)22-17(25)20-10-4-2-1-3-5-10/h1-7,13-14,21H,8H2,(H,23,24)(H2,20,22,25) |
InChi Key | UCKHICKHGAOGAP-UHFFFAOYSA-N |
Canonical SMILES | C1C(C2=C(C=C(C=C2Cl)Cl)NC1C(=O)O)NC(=O)NC3=CC=CC=C3 |
Isomeric SMILES | C1C(C2=C(C=C(C=C2Cl)Cl)NC1C(=O)O)NC(=O)NC3=CC=CC=C3 |
PubChem CID | 4267713 |
Molecular Weight | 380.23 |
PubChem CID | 121918 |
---|---|
CAS Registry No. | 139051-78-8 |
ChEBI | CHEBI:250344 |
Enter Lot Number to search for COA:
Solubility | Solvent:DMSO, Max Conc. mg/mL: 9.51, Max Conc. mM: 25; Solvent:ethanol, Max Conc. mg/mL: 38.02, Max Conc. mM: 100 |
---|
1. Leeson PD, Carling RW, Moore KW, Moseley AM, Smith JD, Stevenson G, Chan T, Baker R, Foster AC, Grimwood S et al.. (1992) 4-Amido-2-carboxytetrahydroquinolines. Structure-activity relationships for antagonism at the glycine site of the NMDA receptor.. J Med Chem, 35 (11): (1954-68). [PMID:1534584] [10.1021/op500134e] |